The Role of GLP 1 in Fasting-Induced Improved Glycemic Control
Glucacon-like peptide-1 (GLP-1) is a gastrointestinal peptide that plays a crucial role in glucose metabolism. It is secreted by L cells in the intestine in response to food intake and triggers the postprandial secretion of insulin, suppressing glucagon secretion and delaying stomach emptying. Recent studies have highlighted the importance of GLP-1 in fasting-induced improved glycemic control, making it an attractive area of research in the management of type 2 diabetes.
The Role of GLP-1 in Fasting-Induced Improved Glycemic Control
GLP-1 has been shown to improve glycemic control by increasing insulin sensitivity, reducing glucagon secretion, and promoting weight loss. In fasting-induced conditions, GLP-1 has been demonstrated to play a crucial role in maintaining glycemic control by suppressing glucagon secretion and enhancing glucose-dependent insulin secretion. This is particularly important in individuals with type 2 diabetes, where impaired insulin secretion and increased glucagon levels contribute to hyperglycemia.
Mechanism of Action of GLP-1 in Fasting-Induced Improved Glycemic Control
The mechanism of action of GLP-1 in fasting-induced improved glycemic control involves the suppression of glucagon secretion and the enhancement of glucose-dependent insulin secretion. In the absence of food, GLP-1 levels decrease, and glucagon secretion increases, contributing to hyperglycemia. However, in individuals with type 2 diabetes, GLP-1 levels are often impaired, leading to increased glucagon secretion and reduced insulin secretion. By enhancing glucose-dependent insulin secretion and suppressing glucagon secretion, GLP-1 improves glycemic control and reduces the risk of hypoglycemia.
